The activating protein-1 transcription factor, in particular the Jun proteins play critical roles in the regulation of cell proliferation and tumor progression. To study the potential clinical relevance of interfering with JunB expression, we generated retroviruses expressing short hairpin RNA. Reduction of JunB levels causes increased proliferation and tumorigenicity in wild-type murine fibroblasts, whereas in c-Jun knockout cells p53-independent cell cycle arrest and apoptosis are induced. Using melanoma-derived B16-F10 cancer cells the combination of JunB knockdown and c-Jun/JNK inactivation leads to cell cycle arrest and apoptosis-inducing factor-dependent apoptosis. Furthermore, the combined treatment extends survival of mice inoculated with the tumor cells. These results indicate that in the absence of c-Jun, JunB can act as a tumor promoter and inactivation of both, c-Jun and JunB, could provide a valuable strategy for antitumor intervention.
Introduction
The activating protein-1 (AP-1) is a transcription factor consisting of homodimers between Jun (c-Jun, JunB and JunD) proteins or heterodimers between Jun and Fos (c-Fos, FosB, Fra1 and Fra2) families (Eferl and Wagner, 2003) . Originally, these proteins were identified as being the cellular counterparts of chicken-and mousetransforming viral genes, and therefore c-jun and c-fos were defined as proto-oncogenes Bohmann et al., 1987; Rauscher et al., 1988) . Moreover, AP-1 induction and activation is a downstream event of various signal transduction cascades and has therefore been implicated in fundamental cellular processes including differentiation, cell proliferation, oncogenic transformation and apoptosis (Zenz and Wagner, 2006) .
The Jun proteins share many biochemical properties but differ significantly in their biological functions. Regarding tumorigenesis, c-Jun is frequently found overexpressed in human cancers (Zhang et al., 2005; Vleugel et al., 2006) . Although, to date, there is no evidence of c-jun gene activation, amplifications or recurrent chromosomal translocations, many of the mutations that have been identified in human cancers involve c-Jun upstream activators (Vogt, 2002) . Moreover, a direct implication of ERK/JNK/c-Jun in human melanomas was recently demonstrated, with c-Jun being overexpressed in a large fraction of human melanoma samples (Lopez-Bergami et al., 2007) , while Mariani et al. showed a direct correlation between c-Jun and the aggressiveness of human liposarcomas. In addition, several mouse models showed that c-Jun is required for tumor progression (Bowden et al., 1994; , and is dependent, in part, on Jun N-terminal kinases (JNKs) for activation and stabilization (Nateri et al., 2005) . On the other hand, the role of JunB in tumor development is less defined. Overexpression of JunB has been reported in human cancers (Mao et al., 2003; Rassidakis et al., 2005) , whereas several studies indicated that JunB can inhibit cellular transformation acting as a tumor suppressor in humans and mice (Joseloff and Bowden, 1997; Szremska et al., 2003; Passegue et al., 2004) .
To clarify the role of JunB in tumor progression, we have investigated the therapeutic potential of reducing JunB expression in transformed cells using RNA interference (RNAi) technology. JunB knockdown leads to increased cell numbers and tumorigenicity in wildtype fibroblasts, whereas in c-Jun knockout cells we observed apoptosis and impaired proliferation. We have also addressed the clinical relevance of these findings using the melanoma-derived B16-F10 cells treated with a combination of the SP600125 inhibitor of JNK/c-Jun (Bennett et al., 2001 ) and short hairpin RNA (shRNA) JunB expressing retroviruses.
Results

Knockdown of JunB protein increases c-Jun levels and the proliferation of immortalized fibroblasts
Retroviruses expressing shRNA against JunB were constructed and used to infect 3T3-immortalized mouse fibroblasts. Of the three shRNAs tested, one led to at least 40% inhibition of JunB, while the others had marginal effects on protein expression and were used as scramble shRNAs. Interestingly, the knockdown of JunB caused a 75% upregulation in c-Jun but no change in JunD levels ( Figure 1a) . Immunofluorescence analyses confirmed the specific knockdown of JunB and the subsequent upregulation of c-Jun (Supplementary Figure 1a) ; RNase protection assay indicated that the increase in c-Jun occurred at mRNA level (Supplementary Figure 1b) . This effect was specific, since c-Jun protein levels were not affected by the shRNA against JunB when used in JunB knockout fibroblasts (Supplementary Figure 1c) .
We next analysed AP-1 activity upon JunB knockdown using a reporter assay. As shown in Figure 1b , reduced levels of JunB led to a significant increase in AP-1 activity measured using a collagenase promoter reporter construct. Moreover, shRNA JunB fibroblasts displayed decreased doubling-time and higher saturation densities (25%) compared to control cells ( Figure 1c ). In JunB knockout fibroblasts the shRNA JunB did not affect cell numbers indicating that the effect is JunB-dependent (Supplementary Figure 1d) . To investigate the expression of genes involved in cell cycle progression, subconfluent serum-deprived cells were restimulated with 10% fetal bovine serum to induce cell cycle re-entry and protein extracts were analysed by western blotting at different times. As shown in Figure 1d , the levels of cyclin A were elevated in retro shRNA JunB infected cells, while CDK2 expression was decreased, cyclins E and B remained unchanged, and cyclin D was undetectable (data not shown). These differences were also observed in the G 0 phase. One major function of c-Jun is to antagonize the p53 activity , we observed a slight downregulation of p53; while p21 levels were significantly reduced in shRNA JunB cells (Figure 1d ). To analyse whether p53 mediated the increased proliferation in JunB knockdown cells, p53-deficient fibroblasts (Schreiber et al., 1999) were infected with the shRNA JunB retroviruses. As shown in Figures 1e and f, reducing JunB levels induced a similar c-Jun upregulation and increased cell numbers, indicating that the effects of JunB knockdown are p53-independent.
The regulation of cell proliferation by AP-1 might be crucial for the development of tumors; fibroblasts with reduced levels of JunB displayed significantly enhanced tumor potential in nude mice compared with the control cells (Figure 1g ). Four weeks after inoculation, western blotting revealed increased c-Jun levels in the shRNA JunB tumors, while JunB, p53 and p21 levels were decreased ( Figure 1h ). We cannot exclude a contribution of p53 to this phenotype, since both p53 À/À and p53
JunB knockdown fibroblasts did not induce significant tumors in nude mice (data not shown).
Absence of c-Jun results in apoptosis induction after JunB knockdown To address the contribution of c-Jun in the JunB knockdown induced hyperproliferative phenotype, we made use of c-Jun knockout fibroblasts (Schreiber et al., 1999) . Interestingly, cells lacking c-Jun have increased levels of JunB ( Supplementary Figure 2) , which could be significantly decreased using the same shRNA knockdown strategy (Figure 2a ). Reducing JunB levels induced a drastic decrease in viable cell numbers ( Figure 2b ) and Ki67 staining, indicative of impaired proliferation ( Figure 2c ). In addition, 5 days after retrovirus infection we observed that a significant number of shRNA JunB cells shrank, rounded up and detached from the plates, suggesting that apoptosis had occurred, while the empty retro control cells remained attached to the dishes and showed normal morphology. Fluorescence microscopy of 4 0 ,6-diamidino-2-phenylindole (DAPI) staining enabled a direct visualization of apoptotic cells, which underwent compaction and nuclear chromatin fragmentation ( Figure 2d ). This was confirmed using annexin Vflow cytometry; we found that 49.9% of c-Jun knockout fibroblasts underwent apoptosis after retro shRNA JunB infection against 7.26% in the control cells (Figure 2e ). Moreover, when we investigated caspase activation we observed the induction of the effectors caspase-3 and -8 as judged by the appearance of cleavage products (Figure 2f ).
To determine whether JunB knockdown-induced apoptosis and cell arrest in cells lacking c-Jun is p53-dependent, double-knockout fibroblasts (Schreiber et al., 1999) were infected with the retro shRNA JunB and empty retro as controls (Figure 3a) . Similar to what we observed previously, viable cell counting and Ki67-staining quantification indicated a lower proliferation rate of p53 À/À c-jun À/À shRNA JunB-infected fibroblasts compared to controls (Figures 3b and c) . Furthermore, a significant percentage (32.2%) of p53 À/À c-jun À/À cells with reduced levels of JunB underwent apoptosis 5 days after retrovirus infection, as monitored by DAPI and annexin staining, as well as caspase-3 and -8 activation (Figures 3d-f) . We, therefore, conclude that JunB knockdown induced p53-independent cell arrest and apoptosis in cells lacking c-Jun. Combination of JunB knockdown and the pharmacological JNK/c-Jun inhibitor SP600125 leads to cytotoxic effect in the B16-F10 cancer cells SP600125 (SP) is a recently described inhibitor of JNK/ c-Jun (Bennett et al., 2001 ). This drug acts as a reversible ATP-competitive inhibitor of JNK, and has been shown to exhibit a selectivity of >20-fold relative to other tested kinases. Recent data show that SP inhibits cancer cell proliferation and tumor growth in mice (Ennis et al., 2005) . Since increased c-Jun levels were associated with human melanomas (Choi et al., 2005; Lopez-Bergami et al., 2007) and based upon the fibroblast results described above, we reasoned that the effects of targeting c-Jun using SP in the melanoma-derived cell c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al line B16-F10 could be enhanced by additional silencing of JunB. As reported previously, SP treatment induced a significant decrease in p-JNK and c-Jun protein levels ( Figure 4a ). Interestingly, we noticed that JunB was upregulated after the addition of SP, similar to the c-Jun knockout cells. However, the JunB levels were efficiently suppressed using the shRNA JunB retroviruses ( Figure 4a ). As shown in Figure 4b , the SP drug led to a significant decrease in AP-1 activity, measured using reporter assays. In addition, western blotting indicated that SP increased p53 and p21 levels (Supplementary Figure 3a) . Viable cell counts and Ki67 staining indicated a similar reduction in the proliferation rate after SP treatment of empty retro or shRNA JunB cells (Figures 4c and d) , whereas the fluorescence-activated cell sorter (FACS) analysis revealed that the cell arrest occurred in the G 2 / M phase (Figure 4e ). Furthermore, levels of cyclins E, A and D were reduced and cyclin B was increased after SP treatment, indicating that these cells were not able to proceed through mitosis (Supplementary Figure 3b) . Interestingly, when apoptotic cells were monitored by c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al annexin V and propidium iodide (PI) staining, we observed that the combination of SP treatment and shRNA JunB strongly increased the percentage of cells in both early and late apoptotic state in a drug concentration-dependent manner (Figure 4f ).
In conclusion, a low dose of SP treatment induced a comparable cytostatic effect on the control and JunB shRNA infected cells; however, a higher concentration of the drug gave rise to a potent cytotoxic effect selectively in B16-F10 cells with reduced JunB levels.
PARP-1 and AIF are involved in B16-F10 cell death induced by the SP-shRNA JunB combined treatment To study the involvement of caspase-dependent pathways, in particular, the role of caspase-3 and -8 in the combined shRNA JunB-SP-induced cell death, western c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al blotting and caspase inhibitor assays were performed. The combined treatment failed to induce the cleavage of the executioner caspase-3 and -8, while no significant changes were found in the apoptotic cell levels after Z-VAD.fmk addition (Supplementary Figure 4a and Figure 5a ). Moreover, the SP drug did not induce the cleavage of the major caspase-3/-7 target, the poly (ADP-ribose)polymerase-1 (PARP-1) protein (Supplementary Figure 4b ).
Recent evidence indicates that intact PARP-1 is required for caspase-independent apoptosis mediated by apoptosis-inducing factor (AIF) release from the mitochondria and translocation to the nucleus (Yu et al., 2002) . Therefore, we examined whether PARP-1 was involved in the induced apoptotic cell death. Pretreatment of shRNA JunB-infected B16-F10 cells with 20-mM of SP and the PARP-1-specific inhibitor 1,5-isoquinolinediol (DIQ) strongly attenuated the induced (Figure 5b ). We also observed a significant decrease in the mitochondrial membrane potential (Dc m ) measured by FACS, and reduced levels of the antiapoptotic Bcl-2 protein after the SP addition (Figures 5c and d) , whereas no change was found in Bcl-X L expression. The release of the two proapoptotic factors AIF and cytochrome c from the mitochondria was next examined. As shown by immunofluorescence and western blot analysis, AIF was efficiently released in the apoptotic cells (Figures 6a and b) . In contrast, no cytochrome c release was detected (Figure 6a and Supplementary Figure 4c) . These results are consistent with the recent published data, which suggest specific independent pathways for AIF and cytochrome c release from mitochondria (Artus et al., 2006) .
SP600125 treatment increased the survival of mice inoculated with retro shRNA JunB infected B16-F10 cells Finally, we tested whether the in vitro results of combined anti-JunB/c-Jun strategy have any in vivo relevance for cancer therapy. We inoculated retro shRNA JunB or empty retro-infected B16-F10 cells into the flanks of C57BL/6 mice (n ¼ 8). Once the tumors were palpable (usually 4 days after the inoculation), mice were treated with two administrations of SP (10 mg/kg) i.p. and s.c. every other day. While the empty retro tumors did not show any significant regression following the SP treatment, the same concentration of the drug caused a significant tumor size reduction compared with the controls when mice were inoculated with shRNA JunB cells (not shown). The Kaplan-Meier curves clearly demonstrate that the reduction in tumor size directly correlates with an increase in survival (Figure 7a ). Mice injected with JunB knockdown cells had a median survival of 32 days after the SP treatment, while the untreated shRNA JunB mice had a median survival of 14.5 days, and mice injected with empty retro cells had a median survival of 20 (untreated) and 22 (SP treated) days, respectively. Interestingly, while JunB silencing had no effect on B16-F10 cells proliferation in vitro, it did lead to more aggressive tumors in vivo as indicated by the shorter survival of the inoculated mice. We next analysed the antitumor action in the combination with JunB knockdown and SP treatment by in situ TdT-mediated dUTP nick end labeling (TUNEL) staining. As shown in Figure 7b , cell death was clearly induced after the combined treatment, while no significant apoptosis was detected in the control tumors. Moreover, western blotting revealed upregulation of p53 and p21 proteins (83 and 50%, respectively) between the SP-treated and untreated shRNA JunBinduced tumors (Figure 7c ). Finally, 18 days after the inoculation of the shRNA JunB cells, histological c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al analyses indicated that the untreated tumors had metastasized to the liver, while the SP-treated mice did not suffer macro-or micro-metastasis (Figure 7d) .
Discussion
In the present study, we have used a specific shRNA against JunB in immortalized fibroblasts and demonstrated that knocking down JunB induces transcriptional expression of its antagonistic partner c-Jun, leading to a significant increase in AP-1 activity. In agreement with the previously published data (Chiu et al., 1989) , we postulate that this effect is due to the negative regulation of c-Jun expression by JunB through competition for the AP-1 site within the c-jun promoter. We observed the upregulation of cyclin A and reduction in p21 in this setting, which, in turn, increased the proliferation of immortalized fibroblasts in vitro and their tumorigenicity in nude mice. Interestingly, p53 À/À fibroblasts also showed c-Jun upregulation and higher proliferation rates after JunB knockdown, suggesting that p53 is not crucial for the proliferative effects of JunB silencing.
Consistent with our findings, JunB expression is downregulated in human chronic myeloid leukemias (Yang et al., 2003) and mice lacking this protein in the myeloid lineage develop a myeloproliferative disease showing significant upregulation of c-Jun (Passegue et al., 2001) . On the other hand, we presently demonstrate that silencing JunB in c-Jun knockout cells resulted in a p53-independent cell cycle arrest and apoptosis induction, indicating that c-Jun is critical for the JunB antiproliferative effect and tumor suppressor action, and that in cells lacking c-Jun, JunB can act as a tumor promoter. In support of this hypothesis, genetic experiments have demonstrated that JunB can replace c-Jun during mouse development (Passegue et al., 2002) , and analysis of human samples showed that JunB is overexpressed in certain types of cancer (Mao et al., 2003; Rassidakis et al., 2005) . Therefore, we speculate that if c-Jun can be maintained inactive, JunB could be a good target for cancer intervention. Since the ERK/JNK/c-Jun pathway has been shown to be closely linked to melanoma development, we combined the JNK/c-Jun inhibition by SP with retrovirus-mediated knockdown of JunB as a strategy against the melanoma-derived B16-F10 cancer cells. The SP treatment led to a decrease in c-Jun protein levels but also to a previously unreported, dose-dependent increase in JunB. Here, we demonstrated that with a low dose of the JNK/c-Jun inhibitor, both control and shRNA JunB cancer cells increased p53 and p21 levels and G 2 /M phase arrest, suggesting a JunB-independent cytostatic effect of SP. However, when we increased the drug concentration, cells with reduced levels of JunB induced strong caspase-independent apoptosis, indicating that the toxicity of SP on tumorigenic cells is dosedependent but that it can be significantly enhanced by additional JunB knockdown. These data clearly indicate that, similar to the fibroblast system, inactivation of c-Jun and JunB induces cell death.
AIF was the first identified protein involved in caspase-independent cell death (Susin et al., 1999) . After a cellular insult, AIF cleaves and translocates from the mitochondria to the nucleus and causes caspaseindependent chromatin condensation and DNA fragmentation. It has been suggested that intact activated PARP-1 may be required for AIF release from the mitochondria and for apoptosis induction (Yu et al., 2002) . We have found that the addition of the specific PARP-1 inhibitor significantly reduced cell death in the melanoma cells, implicating PARP-1 in the apoptosis triggered as a consequence of JunB/c-Jun inactivation. Furthermore, combined anti-Jun treatment decreased the mitochondrial membrane potential, reduced the levels of the antiapoptotic Bcl-2 protein and triggered AIF translocation from the mitochondria to the nucleus, indicating that JunB/c-Jun inactivation can induce, in B16-F10 cells, PARP-1-mediated apoptosis activation leading to AIF release from the mitochondria in a caspase-independent manner. How PARP-1 is activated in these cells as well as in other settings is presently unknown; however, this type of PARP-1/AIF-mediated cell death seems to be particularly effective in the cancer cells (Kang et al., 2004; Galluzzi et al., 2006) .
It has been previously reported that the JNK inhibitor cause tumor regression in vivo (Ennis et al., 2005; Gururajan et al., 2005) , we therefore assessed the combined anti-JunB/c-Jun strategy against melanoma cells in the C57BL/6 mice strain using conditions where the SP treatment alone had no significant effect. We observed a striking decrease in tumor size, apoptosis induction and a significant increase in the survival of mice inoculated with the JunB knockdown cells after the SP administration, demonstrating the enhanced potential therapeutics in vivo of the JNK inhibitor in cells lacking JunB.
The major concern about targeting transcription factors in cancer therapy is that it might result in serious side effects by affecting normal cells. However, c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al we believe that double Jun inactivation could be of interest in certain types of cancer where the drug/ shRNA could be delivered locally or selectively targeted to the transformed cells. In the past few years, cancer therapy strategies targeting AP-1 have been mainly focused on c-Jun/JNK inactivation (Libermann and Zerbini, 2006) . The data presented here suggest that because of the protumorigenic role of JunB in cells lacking c-Jun, additional inhibition of JunB could enhance the efficiency of such therapies.
Materials and methods
Reagents SP600125 and DAPI were purchased from Calbiochem (San Diego, CA, USA). Z-VAD.fmk was purchased from Tocris Bioscience. DIQ was purchased from Sigma (St Louis, MO, USA).
Retrovirus vector construction
We have followed previously described methods (Brummelkamp et al., 2002) to generate the pRetro-RNAi-JunB (pRiJB) plasmid with minor modifications. Specifically, the pRetroSuper vector was digested with BglII and XhoI and ligated with annealed synthetic oligos. Three RNAi retrovirus vectors (pRiJB-1, -2 and -3) were tested in 3T3 cells; the synthetic DNA sequence corresponding to the shRNAs against JunB (GCAACGGCGTGATCACGAC, CACGACTACAAACTC CTGA and GAGCGCATCAAAGTGGAGC) were selected using the JunB cDNA sequence available in GenBank (accession number NM_002229).
Cell culture, transfection and infection
, B16-F10 and Phoenix Eco cells) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Vectors pRiJB-1, -2 and -3 or pRetro-Super was transfected in Phoenix Eco cells using Lipofetamine-Plus (Life Technologies Inc., Gaithersburg, MA, USA), following the manufacturer's protocols. Forty-eight hours after the transfection, the viral supernatant was filtered through a 0.45-mm filter and used for the infection of the cells after the addition of 4 mg/ml of polybrene. The cells were infected overnight and allowed to recover for 24 h with fresh medium before selection with 2 mg/ml of puromycin.
Measurement of AP-1 Activity
Cells were transfected with the AP-1-luciferase reporter gene plasmid carrying the collagenase promoter (p-73col-luc (Deng and Karin, 1993) ) or with the control plasmid without the AP-1 site and the pRL-tk-luc plasmid (Promega, Madison, WI, USA) to normalize the transfection efficiency. After 24 h, the activity was determined using a Promega luciferase assay kit following the manufacturer's protocols. Data are represented in relative firefly luciferase units normalized by the relative Renilla luciferase units and reported as the mean7s.d. of three individual experiments.
Western blotting
Equal amounts of proteins, as determined by the BCA protein micro assay (Bio-Rad, Hercules, CA, USA), were resolved by sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) according to the standard procedures.
The primary antibodies used were JunB, JunD, cyclin E, cyclin A, cyclin D, cyclin B, p53, Bcl-2 and caspase-8 (Santa Cruz Biotechonology Inc., Santa Cruz, CA, USA); c-Jun, CDK2, p21 and manganese superoxide dismutase (Transduction Laboratories, Lexington, KY, USA); phospho-JNK, caspase-3, BclX L and AIF (Cell Signaling, Danvers, MA, USA); PARP-1 (Promega) and actin and a-tubulin (Sigma). The protein was detected by chemoluminescence, using the corresponding Hp-conjugated antibody (Dako, Cambridge, UK).
Immunofluorescence
The immunofluorescence was performed as described previously (Gurzov and Izquierdo, 2006) . Primary antibodies used were rabbit anti-JunB (Santa Cruz Biotechonology Inc.), mouse anti-c-Jun (Transduction Laboratories), mouse anticytochrome-c (BD Biosciences, San Jose, CA, USA), rabbit anti-Ki67 (Novocastra, Newcastle, UK) and rabbit anti-AIF (Cell Signaling).
FACS analysis
Apoptosis was analysed by annexin V/PI staining. Briefly, 5 Â 10 5 cells were collected, washed in cold PBS and incubated in binding buffer containing fluorescein isothiocyanate (FITC)-labeled annexin V (BD Biosciences) and PI (Sigma) for 15 min at room temperature in the dark. The samples were then analysed by flow cytometry by FACS.
For cell cycle and sub-G 0 analysis, the cells were harvested by trypsin digestion, washed with cold PBS and resuspended in 70% ethanol at 41C for at least 8 h. The fixed cells were collected by brief centrifugation and resuspended in PBS containing PI (5 mg/ml)/RNase A (25 mg/ml). After incubation for 30 min at room temperature, the samples were subjected to FACS.
The measurement of Dc m was performed as described previously (Marchetti et al., 1996) . Briefly, shRNA JunB or empty retro cells were exposed to 20-mM SP600125 for 24 h; then, the cells were incubated in 50 nmol/l of 3,3 0 -dihexyloxacarboxyanine iodide (DiOC 6 ) (Invitrogen, Carlsbad, CA, USA) and PI (5 mg/ml)/RNase A (25 mg/ml) at 371C for 10 min, harvested by trypsinization and washed with cold PBS solution. Dc m were determined by FACS analysis.
Tumor xenografts and SP treatment Empty retro or retro shRNA JunB 3T3 infected cells (1 Â 10 6 ) were inoculated subcutaneously into 8-to 12-week-old congenitally athymic female Swiss nude mice (from the Mice Facility of the 'Severo Ochoa' Molecular Biology Center, Spain). The tumors were measured weekly, and the tumor volume was calculated (p/6 Â (length Â width Â height)).
B16-F10 infected cells (1.5 Â 10 6 ) were inoculated subcutaneously into 8-to 12-week-old C57BL/6 female mice (Harlan, Spain) on day 0. For the SP treatment, the animals were injected with the drug (10 mg/kg) i.p. on days 4 and 8 and s.c. on days 6 and 10. For animal care and handling, we have strictly followed the legislation and guidelines in our country (Spanish Royal Decree 1201 , the ones from the British UKCCCR committee for the welfare of animals in experimental neoplasia (revised version of July 1997) and the European Union (2003/65/CE from the European Parliament and Council July 2003).
Histological procedures
The tumors and organs were washed with 10 ml of PBS and fixed in formaldehyde 10% in phosphate buffer, dehydrated and embedded in paraffin wax. Apoptosis was detected by c-Jun/JunB inactivation induces apoptosis in cancer cells EN Gurzov et al in situ TUNEL assay. Briefly, sections were deparaffinized in xylene and rehydrated before analysis. Later, endogenous peroxidase activity was quenched in 3% hydrogen peroxide for 20 min, the sections were treated with proteinase K (20 mg/ml in 10-mM Tris-HCl, pH 7.6) at 371C for 20 min before labeling with terminal deoxynucleotidyl (TdT) (Roche, Basel, Switzerland) and biotinylated dUTP (Roche) in 140-mM potassium cacodylate/1.5-mM cobalt chloride/0.2-mM DTT, pH 7.2, at 371C for 30 min in a humidified chamber. TdT was omitted from the control slides. Then, washed sections were incubated with anti-digoxigenin (Roche, 1/200) for 90 min and 40 min with the anti-mouse Texas red-conjugated secondary antibody (Invitrogen, 1/500). DAPI was used for DNA staining. At least five different sections were analysed from two animals in each condition.
